Notably, amplification of the MYCN transcription factor is one of the most powerful adverse prognostic factors in neuroblastoma [14] and we have previously demonstrated that PTPRD is expressed at significantly lower levels in MYCN amplified neuroblastoma relative to non-MYCN amplified tumors [10]. This evidence concerns the gene MYCN and neuroblastoma.